Phaseline

Companies › Novadip Biosciences

Novadip Biosciences: clinical trials, targets and expected readouts

2 active drug programs in 4 registered trials: 3 Phase 1, 1 Phase 3; Other; next expected readout Jul 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NVD003
Autologous 3D osteogenic implant for bone reconstruction
–Phase 3Congenital Pseudarthrosis of Tibia; Recalcitrant Lower Limb NonunionJul 2027
NVDX3
Implantable device for degenerative lumbar spondylolisthesis
–Phase 1Degenerative Lumbar Spondylolisthesis; Distal Radius FracturesMar 2036

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05961956NVDX3Phase 1Degenerative Lumbar SpondylolisthesisOtherApr 2026
NCT07112443NVD003Phase 3Congenital Pseudarthrosis of TibiaOtherJul 2027
NCT06335394NVD003Phase 1Recalcitrant Lower Limb NonunionOtherMay 2028
NCT06532253NVDX3Phase 1Distal Radius FracturesOtherMar 2036

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Harmony Biosciences Management Tortugas Neuroscience Atsena Therapeutics Shanghai Ark Biopharmaceutical Heron Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.